Predictors of corticosteroid-dependent and corticosteroid-refractory inflammatory bowel disease: Analysis of a Chinese cohort study

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 8, 2009, Pages 843-854

  Chow, D K L ^a,b   Sung, J J Y ^b   Tsoi, K K F ^b   Wong, V W S ^b   Wu, J C Y ^b   Leong, R W L ^c   Chan, F K L ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; THROMBOCYTOSIS; TOTAL PARENTERAL NUTRITION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ABDOMINAL PAIN; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CHINA; COHORT STUDIES; COLITIS, ULCERATIVE; DIARRHEA; FEMALE; FEVER; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PARENTERAL NUTRITION; PHENOTYPE; RISK FACTORS; THROMBOCYTOSIS; YOUNG ADULT;

EID: 62849111962     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.03944.x     Document Type: Article

References (33)

1. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W, American Gastroenterological Association. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006 130 : 935 9.
2. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. BMJ 1955 2 : 1041 8.
3. Summers RW, Switz DM, Sessions JT Jr., et al. National cooperative Crohn's disease study: results of drug treatment. Gastroenterology 1979 77 : 847 69.
4. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984 86 : 249 66.
5. Faubion WJ, Loftus EJ, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001 121 : 255 60.
6. Toruner M, Loftus EV Jr., Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008 134 : 929 36.
7. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994 35 : 360 2.
8. Ho G-T, Chiam P, Drummond H, et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006 24 : 319 30.
9. Hutfless SM, Weng X, Liu L, et al. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology 2007 133 : 1779 86.
10. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomized trial. Lancet 2008 371 : 660 7.
11. Lautenbach E, Berlin JA, Lichtenstein GR. Risk factors for early postoperative recurrence of Crohn's disease. Gastroenterology 1998 115 : 259 67.
12. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006 130 : 650 6.
13. Tung J, Loftus EV Jr., Freese DK, et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2006 12 : 1093 100.
14. Franchimont DP, Louis E, Croes F, et al. Clinical pattern of corticosteroid dependent Crohn's disease. Eur J Gastroenterol Hepatol 1998 10 : 821 5.
15. Gelbmann CM, Rogler G, Gross V, et al. Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease. Am J Gastroenterol 2002 97 : 1438 45.
16. Papi C, Festa V, Leandro G, et al. Long-term outcome of Crohn's disease following corticosteroid-induced remission. Am J Gastroenterol 2007 102 : 814 9.
17. Census and Statistics Department, the government of the Hong Kong Special Administrative Region. Table 141. Population by District Council District, 1996, 2001 and 2006. http://www.censtatd.gov.hk/hong-kong-statistics/ statistical-tables/index.jsp?charset1D=1&subject1D=1&tableID=141.
18. Leong RW, Lau JY, Sung JJY. The epidemiology and phenotype of Crohn's disease in the Chinese population. Inflamm Bowel Dis 2004 10 : 646 51.
19. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989 170 : 2 6.
20. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005 19 (SupplA 5 36.
21. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007 369 : 1641 57.
22. Carter MJ, Lobo AJ, Travis SP, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004 53 (suppl 5 V1 16.
23. Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 2004 99 : 1371 85.
24. Chow DK, Leong RW, Lai LH, et al. Changes in Crohn's disease phenotype over time in the Chinese population: Validation of the Montreal Classification System. Inflamm Bowel Dis 2008 14 : 536 41.
25. Farrell RJ, Murphy A, Long A, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000 118 : 279 88.
26. Ritchie JK, Powell-Tuck J, Lennard-Jones JE. Clinical outcome of the first ten years of ulcerative colitis and proctitis. Lancet 1978 1 : 1140 3.
27. Langholz E, Munkholm P, Davidsen M, et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992 103 : 1444 51.
28. Brostrom O, Monsen U, Nordenwall B, et al. Prognosis and mortality of ulcerative colitis in Stockholm County, 1955-1979. Scand J Gastroenterol 1987 22 : 907 13.
29. Lemann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006 130 : 1054 61.
30. Hommes D, Baert F, van Assche G, et al. Management of recent onset Crohn's disease: a controlled, randomized, trial comparing step-up and top-down therapy. Gastroenterology 2005 129 : 371.
31. Colombel JF, Loftus EV Jr., Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004 126 : 19 31.
32. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004 53 : 849 53.
33. Hansen RA, Gartlehner G, Powell GE, et al. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol 2007 5 : 729 35.